As the overexpression of PD-L1 in EGFR-driven lung cancer cells may be a mechanism of immune-tolerance to evade the tumor killing by infiltrating immune cells, the PD-1 and PD-L1 axis can be a reasonable therapeutic target to break the immune-tolerance and to enhance anti-tumor immunity in EGFR-driven lung cancer. This evidence concerns the gene CD274 and lung cancer.